Reflecting on 25 Years of Progress at the DCVMN's Silver Jubilee AGM! It was a privilege to gather for the 25th DCVMN Annual General Meeting—a milestone celebration of two and a half decades dedicated to advancing global vaccine equity and collaboration. A huge thank you to all our distinguished guests, leadership from international organizations including World Health Organization, Gavi, the Vaccine Alliance, CEPI (Coalition for Epidemic Preparedness Innovations), UNICEF, PATH, Pan American Health Organization, Bill & Melinda Gates Foundation, IFC - International Finance Corporation, U.S. International Development Finance Corporation, and several others for their in-person and virtual attendance, and video messages. Thank you to all our amazing panel chairs, insightful speakers, dedicated attendees, and generous sponsors who joined us and made this event memorable. Your presence and contributions truly underscored our shared commitment to a healthier world. We are particularly grateful to our co-hosts, Instituto Butantan and Bio-Manguinhos / Fiocruz, for their invaluable partnership in bringing this AGM to life, and to SINERGIUM Biotech for their support in making the Gala dinner an unforgettable evening. As we look back on this incredible journey, we are already excited for what is to come. We look forward to seeing you all in Bali, Indonesia, for the 26th DCVMN AGM as we continue to work together toward a brighter future. Thank you all for being part of the DCVMN community, and here is to the next 25 years of impact!
Developing Countries Vaccine Manufacturers Network (DCVMN International)’s Post
More Relevant Posts
-
A Quarter Century of Transforming Rare Disease Care in Egypt: A Journey of Impact and Innovation 🌟 Sanofi Egypt has marked a historic milestone: 25th anniversary of the Gaucher Initiative. We were honored to host Sanofi's Rare Disease and Foundation S Global Leadership team reflecting on a legacy that has reshaped rare disease care in Egypt and beyond. Our journey took us through rare disease clinics at three major university hospitals, where we met with patients, each story a testament to resilience and hope. 💪🏻 Engagement included one-of-a-kind Town Hall at Sanofi Egypt premises, uniting our employees in commemorating this landmark milestone in the history of the Egyptian affiliate. In an interactive panel discussion co-moderated by Sherif Abdel Wahab Roushdy and Ghada Michel, joined by distinguished leaders Burcu Eryilmaz, Paul Rowe, MD, ATSF , Alaa Hamed , Bonnie Anderson Hill , and Adrien Delamare-Deboutteville , who shared insights from real life patients’ experiences and reinforcing our commitment to the rare disease community. At a subsequent press conference, leading experts reflected on 25 years of progress and the inspiring role of Project HOPE in empowering Gaucher patients. They highlighted the importance of providing multidisciplinary care in transforming lives and supporting patient integration into the society. The 25th years sustainable commitment attracted the media extensively expressed interest of the humanitarian program, which was an opportunity to raise the public awareness. 🌍 As we commemorate this milestone, #Sanofi_Egypt reaffirms its continuation to its commitment to rare disease patients. The Gaucher Initiative has not only uplifted patients and caregivers but has also established Egyptian physicians as global leaders in Gaucher expertise. 🙏 To every colleague and partner who has been part of this journey, Thank You. Your unwavering dedication has made a profound impact, transformed lives and fueling hope. #GaucherInitiative #RareDiseases #Sanofi_Egypt #FoundationS
-
One of the three areas of this collaboration includes "Advancing climate data, sustainable agriculture, and food systems". 🙌 to Bill & Melinda Gates Foundation, Novo Nordisk and Wellcome Trust. Fantastic to see this from leaders at this level and gives us motivation to keep innovating at I/O Agri #agricultureemissions #agriculture #sustainability #climatech #agritech
Hej from Denmark, where we’re announcing a new partnership between the Bill & Melinda Gates Foundation, Novo Nordisk Foundation, and Wellcome Trust to support the next generation of solutions to some of the world’s toughest challenges. This three-year, $300 million commitment will fund research and development in three key areas: climate and sustainability, infectious diseases, and the interplay between nutrition, immunity, disease, and developmental outcomes. I’m grateful to our partners and to the Gates Foundation team that helped make it happen. Let’s get to work.
-
In the fight against the global health crisis of antibiotic resistance, collaboration is key. That’s why we’re excited to highlight the AMR-Alliance, an ambitious initiative founded by Novo Nordisk Foundation, Pharmadanmark, and Pfizer Denmark in the fall of 2023. Today, the alliance boasts over 30 diverse member organizations, including universities, hospitals, patient associations, unions, foundations, and leading biotech and life science companies. And the numbers are growing! We are thrilled to announce the launch of our new website, featuring interactive elements that highlight the initiatives and mission. 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗶𝘁 𝗵𝗲𝗿𝗲: https://amr-alliancen.dk/ 🛡️ 𝗧𝗵𝗲 𝗠𝗶𝘀𝘀𝗶𝗼𝗻: The AMR-Alliance is dedicated to addressing the critical issue of antibiotic resistance from multiple angles—patient care, public health, societal impact, and the Danish life science industry. The approach includes public hearings, debates, conferences, and continuous educational efforts to ensure both the public and healthcare professionals are well-informed on the proper use of antibiotics. 🔬 𝗙𝗼𝗰𝘂𝘀 𝗔𝗿𝗲𝗮𝘀: 𝟭 Vaccination: Promoting better use of vaccinations to reduce the need for antibiotics. 𝟮 Diagnostics: Advancing and optimizing diagnostic methods 𝟯. New Antibiotics: Supporting development and access. 𝟰. Innovative Treatments: Curing chronic bacterial infections. Denmark already leads in stewardship and the OneHealth approach, and the AMR-Alliance is committed to maintaining and expanding this focus. Together, we can build a future where antibiotic resistance is effectively managed, ensuring healthier lives for all. Join us in this critical endeavor. Share your thoughts, get involved, and let's work together for a healthier future! #AMRAlliance #AntibioticResistance #LifeScience #HealthInnovation #NovoNordiskFoundation #Pharmadanmark #PfizerDenmark #OneHealth #PublicHealth #Innovation Thomas Richter Peter Thøgersen Jonas Skov Korsgaard Line Emilie Fedders Nicolai Lysgaard Thomsen Anders Chanruk Larsen Jakob Wilms
-
-
Last week our team was in Ho Chi Minh City in Vietnam at the kick off meetings for the collaborators on the AWaRe1 Project. The AWaRe1 Project is a Wellcome Trust-funded, four-year initiative aimed at identifying and transforming antibiotic prescribing practices. Together, we are developing an innovative framework for antibiotic prescribing surveillance, benchmarking, and conducting population-based interventional trials to optimize antibiotic use.
✨ Exciting Kick-Off for the AWaRe1 Project in Vietnam! ✨ We are thrilled to welcome all our AWaRe1 collaborators to the kick-off meeting in Ho Chi Minh City, Vietnam. A heartfelt thank you to the incredible @OUCRUVietnam team for hosting us, providing invaluable support, and sharing their expertise with the consortium. The AWaRe1 Project is a @WellcomeTrust-funded, four-year initiative aimed at identifying and transforming antibiotic prescribing practices. Together, we are developing an innovative framework for antibiotic prescribing surveillance, benchmarking, and conducting population-based interventional trials to optimize antibiotic use. Our work is divided into three core workflows: 1️⃣ WS1: Developing novel methodologies to assess antibiotic exposure in primary care, leveraging geo-spatial mapping approaches. 2️⃣ WS2: Led by KTU in Cape Town, this workflow builds on the AWaRe Book’s primary care respiratory tract infection (RTI) guidance to create localized, country-specific educational and process interventions for primary healthcare clinics. 3️⃣ WS3: Testing these interventions through a large-scale, pragmatic cluster randomized controlled trial (RCT). Over the last three days, we’ve come together as a diverse and dynamic group to coordinate our efforts, refine our delivery plan, and chart the best path forward for the years ahead. We look forward to driving meaningful impact in antibiotic stewardship and improving global health outcomes through this collaboration. Stay tuned for updates as we progress! #HealthcareInnovation #AntibioticStewardship #GlobalHealth #AWaRe1Project St George's, University of London King's College London Oxford University Clinical Research Unit The Health Foundation South Africa University of East Anglia Stichting Radboud Universitair Medisch Centrum Hanoi University Fondazione ISI - Innovazione e Sviluppo Imprenditoriale Universitas Gadjah Mada (UGM) INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH BANGLADESH Knowledge Translation Unit Lagos State University College of Medicine (LASUCOM), Ikeja Wellcome Trust
-
-
Scrum Master & Agile Coach | SAFe Environment Enhancement, Agile Methods, Servant & Change Leader, Emotional Intelligence and Innovative Mindset
Corporate Social Responsibility-CSR of global business is to have a communo-centric approach to their business model in giving back to the global community that keeps their business profitably sustainable. This goes a long way to cement the business agenda as it makes the community and society a better place for all to live in.
Hej from Denmark, where we’re announcing a new partnership between the Bill & Melinda Gates Foundation, Novo Nordisk Foundation, and Wellcome Trust to support the next generation of solutions to some of the world’s toughest challenges. This three-year, $300 million commitment will fund research and development in three key areas: climate and sustainability, infectious diseases, and the interplay between nutrition, immunity, disease, and developmental outcomes. I’m grateful to our partners and to the Gates Foundation team that helped make it happen. Let’s get to work.
Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact
gatesfoundation.org
-
Health support and education should be the focus of the human development
Hej from Denmark, where we’re announcing a new partnership between the Bill & Melinda Gates Foundation, Novo Nordisk Foundation, and Wellcome Trust to support the next generation of solutions to some of the world’s toughest challenges. This three-year, $300 million commitment will fund research and development in three key areas: climate and sustainability, infectious diseases, and the interplay between nutrition, immunity, disease, and developmental outcomes. I’m grateful to our partners and to the Gates Foundation team that helped make it happen. Let’s get to work.
Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact
gatesfoundation.org
-
Holidays and gratitude... With the holidays finally here, I have a moment to look back on an intense and rewarding year in the Biodesign course. It’s been a truly hands-on experience, from coming up with ideas to developing a full business concept. None of this would have been possible without the incredible support of my team Sam Cogan Dana Farah, our mentors, and the course leaders. I want to give special thanks to Dr. Anat Stern, who opened our eyes to the significant issue of penicillin allergy mislabeling. Her dedication to patient safety inspired us to work on a solution that could make a real difference. In fact, we dedicated the reflection section of our final report to her, as a recognition of her guidance and the impact she had on our project. While we won’t be pursuing this specific project further, the lessons we’ve learned along the way were invaluable. We’re now exploring new opportunities in a completely different field, far from infections, but still in the rapidly growing and exciting space of healthcare innovation. To be continued... #Biodesign Israel, Yona Vaisbuch, Sagit Eshel, Oded Kraft, @Dr. Anat Shtern, @Eyal Zohar, @Dr. Ivan Gur, Fabian Schvartzman, @Charlie Chaim Haber, and @Adi Fechter #Biodesign #MedTech #PatientSafety #Innovation #Biotech #Entrepreneurship #Gratitude #HealthcareInnovation
🌟 We are excited to Present Biodesign Israel 4th Cohort graduate teams🌟 From groundbreaking projects to inspiring solutions, this cohort has demonstrated extraordinary creativity and commitment. We can’t wait to share their successes and the incredible potential they bring to the field. We’re thrilled to showcase their hard work and celebrate their accomplishments. Meet AllerGuide ⬇ Ofri Meller-Peri Dana Farah Sam Cogan A century ago, simple infections were deadly due to the lack of effective treatments. Antibiotics transformed this, but the overuse of broad-spectrum antibiotics now threatens us with antibiotic resistance. AllerGuide addresses a critical issue: 10% of Americans are labeled as allergic to penicillin, yet only 1% truly are, affecting 33 million people. This mislabeling leads to unnecessary use of broad-spectrum antibiotics, resulting in antibiotic resistance, increased healthcare costs, and longer hospital stays. AllerGuide is a real time decision support system to help doctors make more informed decisions regarding patients with reported Antibiotic Allergies. This ensures optimal patient care and combats antibiotic resistance, a global threat. #Biodesign #Innovation #Teamwork #Graduation #FutureLeaders Yona Vaisbuch Si Buchbut
-
MD, PhD. Professor of Genetics @ University of Kinshasa, DR Congo PI of the African Rare Diseases Initiative (ARDI) Directeur du Réseau National Maladies Rares et Non-Diagnostiquées, RD Congo
For this 2025 #EDCTP call, the Center for Human Genetics of the University of #Kinshasa is interested in participating in #TB and #Malaria trials with pharmacogenomics assessments of #vaccines and #drugs. Any #Consortium forming and/or preparing an application for #TB or #Malaria vaccine and drug development can reach out to me. Looking forward to succesful collaborations. Hypolite Muhindo Mavoko Global Health EDCTP3 European & Developing Countries Clinical Trials Partnership (EDCTP)
⚡ The Global Health EDCTP3 Work Programme 2025 is published! With an indicative budget of €214 million across four calls for proposals and seven topics, this is our largest and most ambitious Work Programme to date. In 2025, our calls will support: 🔬 Research and Innovation Actions (RIA) 🤝 Coordination and Support Actions (CSA). They will address the following topics: 🔹 Vaccines for reducing the disease burden of #tuberculosis in sub-Saharan Africa 🔹 #Malaria therapeutics and clinical development of new antimalarial candidates 🔹 Accelerating the development of prophylactic vaccines against neglected tropical diseases #NTDs 🔹 Strategic training hubs for #fellowships in public health 🔹 Strengthening the regional #networks of excellence and epidemic preparedness consortia 🔹 Tackling diarrhoeal diseases in the context of #climate and health transformative innovations 🔹 Transformative #innovations in global health. The calls will open in late January 2025 and Info Days will be organised in the coming weeks. Check out the Work Programme 2025 on our website and stay tuned for more info 👇 🔗 https://lnkd.in/e38QbZht ----- Irene Norstedt EU Science, Research and Innovation Michael Makanga European & Developing Countries Clinical Trials Partnership (EDCTP) European Commission EU in Emergencies
-
-
#polishbiotech development & networking 🤝 (biotechnologist, tech transfer, entrepreneur, VC CEO)
‼️Three gigantic institutions working together in the field of bio-innovations ➕ if you add on this how fast new technologies are being created 🧬 ➕speeding this process with AI tools… I dare to say: upcoming years will re-shape humanity. 💡 Central European BioForum
Hej from Denmark, where we’re announcing a new partnership between the Bill & Melinda Gates Foundation, Novo Nordisk Foundation, and Wellcome Trust to support the next generation of solutions to some of the world’s toughest challenges. This three-year, $300 million commitment will fund research and development in three key areas: climate and sustainability, infectious diseases, and the interplay between nutrition, immunity, disease, and developmental outcomes. I’m grateful to our partners and to the Gates Foundation team that helped make it happen. Let’s get to work.
Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact
gatesfoundation.org
-
🆕 Grupo Menarini España and the Germans Trias i Pujol Research Institute (IGTP) have signed an agreement which encompasses two projects focusing on severe infections and antibiotic resistance. Both studies were presented within the framework of the "Scientific exchanges: join us" program, a series of internal meetings showcasing Menarini's scientific collaborations. Dr Mª Lluïsa Pedro-Botet, Roger Cortès Tarragó, Dr Noemí Párraga, and Dr Esteban Reynaga, researchers from the Clinical and Environmental Infectious Diseases (CEID) group at IGTP and Hospital Universitari Germans Trias i Pujol, explained the objectives of their projects. 🗣️ Jordi Barretina, general director of IGTP, states that this agreement with Menarini "strengthens our commitment to excellent research in key areas such as severe infections and antibiotic resistance. This public-private collaboration provides us with a valuable opportunity to continue advancing in the fight against global health challenges". Read more: https://lnkd.in/dDeXQT5M #Research #InfectiousDiseases #Legionella #AntibioticResistance
News
germanstrias.org
